Creating a new treatment to prevent complications in Hemophilia A
Official title: Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A
Funded at State University of New York at Buffalo · NIH-10815822 · Data updated 2026-11-12
This study is testing a new treatment for people with Hemophilia A that aims to help their bodies accept Factor VIII without creating harmful antibodies, making it safer and more effective than current options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | March 27, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $545,700 |
| NIH project number | 5R61HL161818-02 |
| Project ID | NIH-10815822 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Hemophilia A who are at risk of developing inhibitors to Factor VIII.
✕Less likely to help
Patients who do not have Hemophilia A or those who have already developed inhibitors may not benefit from this research.
What this research studies
This research focuses on developing a new form of Factor VIII (FVIII) that aims to prevent the development of inhibitors in patients with Hemophilia A, a serious bleeding disorder. The approach involves using a tolerogenic version of FVIII combined with a special nanoparticle to help the immune system accept the treatment without producing harmful antibodies. By administering this new treatment either orally or intravenously, the researchers hope to reduce the risk of complications associated with traditional FVIII therapies. This innovative method could provide a safer and more effective option for patients who are at risk of developing inhibitors.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of complications and improve the quality of life for patients with Hemophilia A.
How similar studies have gone: While this approach is innovative, previous research has shown promise in using tolerogenic therapies for other autoimmune conditions, suggesting potential for success in this area as well.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Balu-Iyer, Sathy Venkat — State University of New York at Buffalo
- Study coordinator: Balu-Iyer, Sathy Venkat
Related research
Other NIH-funded projects on the same topics.
-
cGMP production of FVIII-making placental cells to help people with Hemophilia A
A new, patient-friendly therapy aims to make FVIII-producing placental cells in the lab to help adults with Hemophilia A, potentially offering a longer-lasting and more affordable treatment.
-
A safer, longer-lasting gene delivery approach for Hemophilia A using improved nonviral vectors
Researchers are testing a new type of nonviral gene delivery that could provide longer expression of a therapeutic gene for adults with Hemophilia A.
-
Hemophilia A: studying why some people develop inhibitors to FVIII across families
This NIH grant funds a multi-year program to follow families affected by severe hemophilia A to understand why some individuals develop antibodies against factor VIII.
-
Intraosseous delivery of gene therapy vectors for hemophilia A
A gene therapy approach using vectors delivered into bone to help people with hemophilia A reduce or eliminate the need for frequent FVIII treatments.
-
Targeting FVIII production to eye-opening blood vessels in hemophilia A
Aims to improve treatment for people with hemophilia A by directing how the body makes clotting factor VIII, using a targeted gene-delivery approach.
-
Platelet-targeted FVIII Gene Therapy for Hemophilia A
A gene therapy approach aims to make platelets carry FVIII to help people with hemophilia A, even if they have inhibitors against FVIII.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.